Adenylosuccinic Acid for Adenylosuccinate Synthase 1 Deficiency

((ASA-CS01) Trial)

This trial tests a new treatment called Adenylosuccinic Acid (ASA-001), which might benefit individuals with ADSS1 deficient myopathy, a muscle condition caused by specific gene mutations. The trial aims to determine the treatment's safety and its potential to slow disease progression. Participants will take the treatment daily for 8 months and visit the clinic every two weeks for tests. The trial seeks adults diagnosed with ADSS1 deficient myopathy who can attend regular clinic visits and adhere to study guidelines. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

You may need to stop or adjust your current medications if they interfere with the trial drug, ASA-001. Your medication doses should not change for at least 4 weeks before the trial starts and during the trial, unless advised by the investigator.

Research has shown that adenylosuccinic acid (ASA-001) has been studied for conditions like Duchenne muscular dystrophy (DMD). In these studies, ASA-001 was generally well-tolerated, with most participants not experiencing serious side effects. However, detailed information about its safety remains limited. This early-stage trial primarily aims to assess how the body processes the drug and to identify any side effects. Although complete safety information is not yet available, previous research on ASA-001 for other conditions suggests potential safety. This trial will provide further insights into its safety profile.¹²³⁴⁵

Most treatments for Adenylosuccinate Synthase 1 Deficiency focus on managing symptoms rather than addressing the root cause. However, the new treatment, ASA-001, stands out because it introduces adenylosuccinic acid, which may directly supplement the deficiency caused by this condition. Researchers are excited about ASA-001 as it targets the underlying enzyme deficiency, potentially offering a more direct and effective approach than current symptom-focused options. This innovative mechanism of action could change how we approach treatment for this rare condition.

Research has shown that adenylosuccinic acid (ASA), the investigational treatment in this trial, may help treat conditions similar to adenylosuccinate synthase 1 (ADSS1) deficiency. In studies with mice, ASA improved muscle function and energy use. Previous studies with humans used ASA in patients with Duchenne muscular dystrophy (DMD) and showed its potential to slow the disease. Early lab findings suggest ASA might protect muscles and manage metabolic stress. While more research is needed, these results indicate that ASA could benefit people with ADSS1 deficiency.¹²³⁶⁷